Semi-xenotransplantation: The regenerative medicine-based approach to immunosuppression-free transplantation and to meet the organ demand

Marcus Salvatori, Andrea Peloso, Ravi Katari, Shay Soker, Jan P. Lerut, Robert J. Stratta, Giuseppe Orlando

Research output: Contribution to journalArticle

Abstract

Although xenografts have always held immeasurable potential as an inexhaustible source of donor organs, immunological barriers and physiological incompatibility have proved to be formidable obstacles to clinical utility. An exciting, new regenerative medicine-based approach termed "semi-xenotransplantation" (SX) seeks to overcome these obstacles by combining the availability and reproducibility of animal organs with the biocompatibility and functionality of human allografts. Compared to conventional xenotransplantation wherein the whole organ is animal-derived, SX grafts are cleansed of their antigenic cellular compartment to produce whole-organ extracellular matrix scaffolds that retain their innate structure and vascular channels. These scaffolds are then repopulated with recipient or donor human stem cells to generate biocompatible semi-xenografts with the structure and function of native human organs. While numerous hurdles must be still overcome in order for SX to become a viable treatment option for end-stage organ failure, the immense potential of SX for meeting the urgent needs for a new source of organs and immunosuppression-free transplantation justifies the interest that the transplant community is committing to the field.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalXenotransplantation
Volume22
Issue number1
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Heterologous Transplantation
Regenerative Medicine
Immunosuppression
Transplantation
Animal Structures
Heterografts
Tissue Donors
Transplants
Population Groups
Extracellular Matrix
Allografts
Blood Vessels
Stem Cells

Keywords

  • cell-on-scaffold-seeding technology
  • extracellular matrix
  • organ bioengineering
  • regenerative medicine
  • semi-xenotransplantation
  • stem cells
  • xenotransplantation

ASJC Scopus subject areas

  • Transplantation
  • Immunology
  • Medicine(all)

Cite this

Semi-xenotransplantation : The regenerative medicine-based approach to immunosuppression-free transplantation and to meet the organ demand. / Salvatori, Marcus; Peloso, Andrea; Katari, Ravi; Soker, Shay; Lerut, Jan P.; Stratta, Robert J.; Orlando, Giuseppe.

In: Xenotransplantation, Vol. 22, No. 1, 01.01.2015, p. 1-6.

Research output: Contribution to journalArticle

Salvatori, Marcus ; Peloso, Andrea ; Katari, Ravi ; Soker, Shay ; Lerut, Jan P. ; Stratta, Robert J. ; Orlando, Giuseppe. / Semi-xenotransplantation : The regenerative medicine-based approach to immunosuppression-free transplantation and to meet the organ demand. In: Xenotransplantation. 2015 ; Vol. 22, No. 1. pp. 1-6.
@article{cd087ffe7e2343cda0ef4b8237b213be,
title = "Semi-xenotransplantation: The regenerative medicine-based approach to immunosuppression-free transplantation and to meet the organ demand",
abstract = "Although xenografts have always held immeasurable potential as an inexhaustible source of donor organs, immunological barriers and physiological incompatibility have proved to be formidable obstacles to clinical utility. An exciting, new regenerative medicine-based approach termed {"}semi-xenotransplantation{"} (SX) seeks to overcome these obstacles by combining the availability and reproducibility of animal organs with the biocompatibility and functionality of human allografts. Compared to conventional xenotransplantation wherein the whole organ is animal-derived, SX grafts are cleansed of their antigenic cellular compartment to produce whole-organ extracellular matrix scaffolds that retain their innate structure and vascular channels. These scaffolds are then repopulated with recipient or donor human stem cells to generate biocompatible semi-xenografts with the structure and function of native human organs. While numerous hurdles must be still overcome in order for SX to become a viable treatment option for end-stage organ failure, the immense potential of SX for meeting the urgent needs for a new source of organs and immunosuppression-free transplantation justifies the interest that the transplant community is committing to the field.",
keywords = "cell-on-scaffold-seeding technology, extracellular matrix, organ bioengineering, regenerative medicine, semi-xenotransplantation, stem cells, xenotransplantation",
author = "Marcus Salvatori and Andrea Peloso and Ravi Katari and Shay Soker and Lerut, {Jan P.} and Stratta, {Robert J.} and Giuseppe Orlando",
year = "2015",
month = "1",
day = "1",
doi = "10.1111/xen.12122",
language = "English",
volume = "22",
pages = "1--6",
journal = "Xenotransplantation",
issn = "0908-665X",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Semi-xenotransplantation

T2 - The regenerative medicine-based approach to immunosuppression-free transplantation and to meet the organ demand

AU - Salvatori, Marcus

AU - Peloso, Andrea

AU - Katari, Ravi

AU - Soker, Shay

AU - Lerut, Jan P.

AU - Stratta, Robert J.

AU - Orlando, Giuseppe

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Although xenografts have always held immeasurable potential as an inexhaustible source of donor organs, immunological barriers and physiological incompatibility have proved to be formidable obstacles to clinical utility. An exciting, new regenerative medicine-based approach termed "semi-xenotransplantation" (SX) seeks to overcome these obstacles by combining the availability and reproducibility of animal organs with the biocompatibility and functionality of human allografts. Compared to conventional xenotransplantation wherein the whole organ is animal-derived, SX grafts are cleansed of their antigenic cellular compartment to produce whole-organ extracellular matrix scaffolds that retain their innate structure and vascular channels. These scaffolds are then repopulated with recipient or donor human stem cells to generate biocompatible semi-xenografts with the structure and function of native human organs. While numerous hurdles must be still overcome in order for SX to become a viable treatment option for end-stage organ failure, the immense potential of SX for meeting the urgent needs for a new source of organs and immunosuppression-free transplantation justifies the interest that the transplant community is committing to the field.

AB - Although xenografts have always held immeasurable potential as an inexhaustible source of donor organs, immunological barriers and physiological incompatibility have proved to be formidable obstacles to clinical utility. An exciting, new regenerative medicine-based approach termed "semi-xenotransplantation" (SX) seeks to overcome these obstacles by combining the availability and reproducibility of animal organs with the biocompatibility and functionality of human allografts. Compared to conventional xenotransplantation wherein the whole organ is animal-derived, SX grafts are cleansed of their antigenic cellular compartment to produce whole-organ extracellular matrix scaffolds that retain their innate structure and vascular channels. These scaffolds are then repopulated with recipient or donor human stem cells to generate biocompatible semi-xenografts with the structure and function of native human organs. While numerous hurdles must be still overcome in order for SX to become a viable treatment option for end-stage organ failure, the immense potential of SX for meeting the urgent needs for a new source of organs and immunosuppression-free transplantation justifies the interest that the transplant community is committing to the field.

KW - cell-on-scaffold-seeding technology

KW - extracellular matrix

KW - organ bioengineering

KW - regenerative medicine

KW - semi-xenotransplantation

KW - stem cells

KW - xenotransplantation

UR - http://www.scopus.com/inward/record.url?scp=84922611793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922611793&partnerID=8YFLogxK

U2 - 10.1111/xen.12122

DO - 10.1111/xen.12122

M3 - Article

C2 - 25041180

AN - SCOPUS:84922611793

VL - 22

SP - 1

EP - 6

JO - Xenotransplantation

JF - Xenotransplantation

SN - 0908-665X

IS - 1

ER -